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Approximately 7 % to 9 % of people in western populations suffer from one of 80 
inflammatory disorders that are collectively defined as autoimmune diseases. This 
translates into 24 million people in the United States of America alone. During the 
development of an autoimmune disease, the immune system is not able to 
distinguish self from foreign antigens and attacks its own healthy tissue. About a 
decade ago, a new autoimmune disease, the N-methyl-D-aspartate receptor 
(NMDAR) encephalitis, has been discovered. NMDARs are frequently expressed in 
nerve cells in the brain and autoantibodies targeting this receptor are thought to 
influence neuronal brain functions. The disease is associated with a prodromal 
phase which includes fever and headache and can lead to psychotic syndromes, 
seizures, decreased levels of consciousness, dyskinesia and often to intensive care 
treatment with autonomic instability and hypoventilation. A trigger for some cases of 
the disease might be an ovarian teratoma.  
Previously, in NMDAR encephalitis, the involvement of anti-NMDAR antibodies has 
been demonstrated in the disease process but an association with other neuronal 
autoantibodies could not be excluded. Therefore, we collected the cerebrospinal 
fluid (CSF) of eight women between 18 and 34 years, five with ovarian teratoma, 
either in the acute phase of the disease or in remission in order to study their 
antibody repertoire. With fluorescence-activated cell sorting (FACS) we separated 
CSF single memory B cells and antibody secreting cells and amplified their 
immunoglobulin heavy and light chains. We generated 170 human monoclonal 
antibodies of NMDAR encephalitis patients representing their antibody repertoire.  
We tested all antibodies on mouse brain sections and human embryonic kidney cells 
(HEK293T) transfected with the NR1 subunit of the NMDAR, which was identified 
as the major autoantigen in NMDAR encephalitis. However, only nine antibodies 
displayed a specific anti-NMDAR reactivity. Previously, it was suggested that the 
target region of the autoantibodies lies in the amino-terminal domain (ATD) and a 
mutation at the amino acid N368Q abolishes binding. We could confirm a loss of 
binding with the N368Q mutation in all nine monoclonal NMDAR autoantibodies. In 
vivo binding of NMDAR epitopes by the monoclonal autoantibodies was further 
demonstrated by intravenous injections of the purified antibodies into mice and 
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subsequent immunohistochemistry (IHC) of brain sections. In addition, functional in 
vitro assays on primary hippocampal neurons revealed surface NMDAR 
downregulation and impairment of NMDAR-mediated glutamate-evoked currents 
and therefore proved the antibody’s inhibitory function on NMDARs.  
To investigate the origin and pathogenesis of NMDAR autoantibodies we analyzed 
whether somatic hypermutations and class switching had occurred. Here, we could 
show that in comparison to all non-NMDAR antibodies in the patients CSF, NMDAR 
autoantibodies presented less somatic hypermutations and some of them even had 
no mutations as compared to the germline. The latter are in general referred to as 
natural occurring antibodies, which indicate incomplete formation of tolerance 
against the NMDAR during B cell development. Besides antibody secreting cells, 
such as plasma cells and plasma blasts, we could also detect memory B cells, which 
are thought to be a risk factor for clinical relapses after therapy. 
Interestingly, only a small amount of autoantibodies is NMDAR specific, over 95 % 
of the non-NMDAR antibodies demonstrated binding to mouse brain epitopes 
including neuronal surface antigens. In mass spectrometry analysis, we could detect 
autoantibodies against a variety of brain epitopes, such as alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor subtype 2 (AMPAR2), inositol          
1,4,5-trisphosphate receptor type 1 (ITPR1), and glial fibrillary acidic protein 
(GFAP). Further investigations of these and additional autoantibodies could reveal 
novel targets, implying a contribution to the diverse clinical picture of NMDAR 
encephalitis.  
In the future, the generated recombinant human monoclonal autoantibodies, against 
NMDAR and non-NMDAR targets, could be used as tools for additional research, 
e.g. together with high resolution synaptic imaging to study molecular mechanisms 
of disease pathogenesis. As titer correlations between patients are ambiguous, 
using these monoclonal NMDAR autoantibodies for standardization of autoantibody 
titers could improve its relevance in clinical settings and ultimately improve 





Ungefähr 7 % bis 9 % der Menschen in westlichen Bevölkerungen leiden an einer 
von 80 entzündlichen Erkrankungen, die kollektiv als Autoimmunkrankheit definiert 
sind. Dies entspricht einer Anzahl von 24 Millionen Menschen allein in den 
Vereinigten Staaten von Amerika. Während der Entwicklung einer 
Autoimmunerkrankung ist das Immunsystem nicht in der Lage, sich selbst von 
fremden Antigenen zu unterscheiden und greift seine eigenen gesunden Zellen und 
Organe an. Vor etwa einem Jahrzehnt wurde eine neue Autoimmunkrankheit 
entdeckt, die N-Methyl-D-Aspartat-Rezeptor-(NMDAR)-Enzephalitis. Besonders 
häufig sind NMDA Rezeptoren in Nervenzellen im Gehirn exprimiert und es wird 
angenommen, dass Autoantikörper, die diesen Rezeptor erkennen, die neuronale 
Signalweiterleitung im Gehirn beeinflussen. Die Krankheit ist mit einer 
Prodromalphase assoziiert, die mit Fieber und Kopfschmerzen beginnt und zu 
psychotischen Syndromen, Anfällen, Bewusstseinsstörungen, Dyskinesien und oft 
zu einer Intensivbehandlung mit Symptomen von autonomer Instabilität und 
Hypoventilation führen kann. Bei einem Teil der NMDAR-Enzephalitis Patienten wird 
das Auftreten eines Ovarialteratoms als Auslöser angenommen.  
Vorherige Studien haben eine mögliche Beteiligung von Anti-NMDAR-
Autoantikörpern aufgezeigt, eine Assoziation mit anderen neuronalen 
Autoantikörpern konnte jedoch nicht ausgeschlossen werden. Daher haben wir den 
Liquor von acht Frauen zwischen 18 und 34 Jahren, fünf mit Ovarialteratom, 
entweder in der akuten Phase der Erkrankung oder in Remission gesammelt um 
das Antikörper-Repertoire zu untersuchen. Mit der Fluoreszenz aktivierten 
Zellsortierung (FACS) trennten wir einzelne B-Gedächtniszellen und Antikörper-
sezernierende Zellen des Liquors von den Patienten und vervielfältigten ihre 
schweren und leichten Immunglobulinketten. Folglich erzeugten wir 170 humane 
monoklonale Antikörper von NMDAR-Enzephalitis Patienten, die deren Antikörper-
Repertoire abbilden. 
Alle monoklonalen Antikörper wurden an Gehirnschnitten von Mäusen und einer 
Zelllinie von menschlichen embryonalen Nierenzellen (HEK293T) getestet, die mit 
der NR1-Untereinheit des NMDA-Rezeptors transfiziert waren. Jedoch zeigten nur 
neun Antikörper eine spezifische Reaktivität gegen den NMDAR. Bisher wurde 
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vermutet, dass die potentielle Zielregion der Autoantikörper in der aminoterminalen 
Domäne (ATD) liegt und insbesondere eine Mutation an der Aminosäure N368Q 
eine Bindung der Antikörper verhindert. In unseren Experimenten mit den humanen 
monoklonalen NMDAR-Autoantikörpern konnten wir das bestätigen. Weiterhin 
konnte die in vivo Bindung an NMDA-Rezeptoren via intravenöser Injektionen der 
monoklonalen Autoantikörper in Mäusen gezeigt werden. Darüber hinaus wiesen 
funktionelle Experimente mit monoklonalen NMDAR Autoantikörpern an primären 
hippocampalen Neuronen darauf hin, dass zum einen NMDA-Rezeptoren 
herunterreguliert und zum anderen die durch NMDA-Rezeptoren vermittelten 
elektrischen Ströme reduziert werden. Diese Experimente belegen abschließend, 
dass NMDAR Autoantikörper alleine dazu in der Lage sind die inhibitorischen 
Funktionen auszuüben, die die primären Symptome der NMDAR Enzephalitis 
auslösen. 
Die Entwicklung von Antikörper-sezernierenden Zellen umfasst Immunglobulin-
Klassenwechsel und somatische Hypermutationen. Im Vergleich zu allen Nicht-
NMDAR-Antikörpern im Patientenliquor zeigten NMDAR Autoantikörper eine 
geringere somatische Hypermutation und einige von ihnen wiesen sogar gar keine 
Mutationen im Vergleich zur Keimbahn auf. Diese werden im Allgemeinen als 
natürlich vorkommende Antikörper bezeichnet, die eine unvollständige 
Toleranzbildung gegenüber dem NMDAR während der B-Zell-Entwicklung anzeigen 
könnten. Neben Antikörper-sezernierenden Zellen, wie Plasmazellen und 
Plasmablasten, konnten wir auch B-Gedächtniszellen erkennen, die die Ursache für 
klinische Rückfälle sein könnten. 
Interessanterweise war nur ein kleiner Teil aller Autoantikörper NMDAR spezifisch, 
über 95 % der Nicht-NMDAR-Antikörper zeigten eine Bindung an 
Mausgehirnepitope einschließlich neuronaler Oberflächenantigene. In 
massenspektrometrischen Analysen konnten wir Autoantikörper gegen eine 
Vielzahl von Gehirnepitopen nachweisen, wie den α-Amino-3-hydroxy-5-methyl-4-
isoxazol-Propionsäure Rezeptor Subtyp 2 (AMPAR2), den Inositol-1,4,5-
trisphosphat-Rezeptor Typ 1 (ITPR1) und saures Gliafaserprotein (GFAP). Weitere 
funktionelle Untersuchungen dieser und weiterer Autoantikörper könnten neue 




In zukünftigen Studien könnten die hergestellten rekombinanten humanen 
monoklonalen Autoantikörper gegen NMDA-Rezeptoren und Nicht-NMDA-
Rezeptoren als Werkzeuge für zusätzliche Untersuchungen dienen, beispielsweise 
zusammen mit hochauflösender synaptischer Bildgebung zur Erforschung 
molekularer Mechanismen. Da die Titerkorrelationen zwischen den Patienten nicht 
eindeutig sind, könnte die Verwendung dieser monoklonalen NMDAR-
Autoantikörper als Standardvergleich zwischen Patienten und Kliniken die Relevanz 
von Antikörpertitern in der therapeutischen Intervention verbessern. 
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1.  Introduction  
1.1.  Autoimmune Encephalitis 
The immune system is a highly effective host defense machinery and protects 
against various pathogens. Under certain conditions in which the immune system is 
not able to distinguish between self and foreign, a so-called autoimmune disease 
develops, where the body’s defense mechanism attacks its own structures. 
Autoimmune diseases are defined as a collection of over 80 inflammatory disorders 
with a prevalence of 7-9 % in the population, affecting more women and often 
developing in middle-aged patients causing significant morbidity and mortality 
(Fairweather et al., 2008; Theofilopoulos et al., 2017; Whitacre, 2001). 
Autoimmune encephalitis (AIE) can be described as an umbrella term of 
heterogeneous neuro-psychiatric disorders caused by the immune system. 
Symptoms associated with autoimmune encephalitis are present in a variable 
clinical picture, starting from mild memory or cognitive impairment, to personality 
changes, psychosis, seizures or movement disorders, leading - in some cases - to 
intensive care treatment (Leypoldt et al., 2015; Tüzün and Dalmau, 2007). In 
general, psychiatric symptoms occur quite often in AIE patients. According to a 
recently reported study, 60 % of the patients display psychiatric symptoms at the 
onset of the disease and 31 % were initially treated in a psychiatric hospital (Herken 
and Prüss, 2017). Several studies point out the importance of an early diagnosis in 
regards to a successful treatment outcome (Finke et al., 2012, 2016; Graus et al., 
2016; Irani et al., 2011; Titulaer et al., 2013). As a consequence, several clinical 
symptoms have been established over the years to facilitate diagnosis of AIE in 
general and subsequently initiate screening for markers. 
The three main diagnostic criteria for AIE are, at first, a subacute onset of less than 
3 months with psychiatric symptoms, like working memory deficits or altered mental 
status such as personality change. Secondly, one or more of the following four 
criteria should apply: cerebrospinal fluid (CSF) pleocytosis, indicated by a count of 
more than five white blood cells per mm3, new focal central nerves system (CNS) 
findings such as impairments of nerves, spinal cord or brain function, not previously 
known seizures and/or hyperintense signals in MRI features in specific areas of the 
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brain. Finally, the reasonable exclusion of alternative causes, for an example virus 
testing to exclude herpes simplex virus encephalitis, or metabolic, and toxic triggers 
(Graus et al., 2016; Ramanathan et al., 2014). Quite recently, it has been shown 
that neuroleptic intolerance should also raise suspicion to test for autoantibodies as 
a sign of AIE especially in psychiatric disorders (Herken and Prüss, 2017; Lejuste 
et al., 2016). 
AIE was initially revealed through syndromes caused by cancer associated immune 
responses and termed as paraneoplastic syndromes. Because these diseases were 
associated with brain infiltrates of cytotoxic T cells attacking the neuronal tissue, the 
response to treatment and recovery was limited (Tüzün and Dalmau, 2007). In this 
case, the detection of autoantibodies functions as a diagnostic marker for the 
underlying tumor. Here, the autoantibodies are not thought to be pathogenic 
themselves (Guan et al., 2016). With the finding of a new category of autoantibodies 
against N-methyl-D-aspartate receptor (NMDAR), these neuronal receptors 
autoantibodies demonstrate to be themselves pathogenic via eliciting functional 
responses (Dalmau, et al., 2007). In addition, patients with NMDAR autoantibodies 
have been more responsive to immune therapy (Dalmau et al., 2008). Soon other 
synaptic or cell-surface autoantibodies were detected such as anti-AMPAR               
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor), anti-LGI1 
(leucine-rich glioma inactivated 1), anti-Caspr2 (contactin-associated protein-like 2), 
and anti-GABAB receptor (γ-aminobutyric acid class B receptor) (Lancaster et al., 
2011; Martinez-Hernandez et al., 2011). Compared to previous described AIE 
patients, NMDAR encephalitis patients indicated differences as they displayed 
infiltrates of B cells and plasma cells, microgliosis, but only a small amount of T cells 
(Dalmau et al., 2007; Tüzün et al., 2009). Therefore, AIE can be divided in two main 
groups. One with classic paraneoplastic neurological syndromes associated with 
neuronal autoantibodies that target intracellular antigens in combination with the 
occurrence of cytotoxic T cell responses and the other with limited T cell response 
but autoantibodies to neuronal surface or synaptic antigens that are able to change 
the structure and function of the target antigen themselves (Leypoldt et al., 2015). 
Besides the important identification of autoantibodies, the ongoing research in the 
field could further reveal that the origin of AIE has several triggers, of which one is 
tumor association. Here, the exact mechanisms how tumors can trigger AIEs are 
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still unknown and need further investigations. The current hypothesis is, that the 
expression of neuronal proteins in tumors can contribute to the break of immune 
tolerance by initiating a B cell immune response towards production of 
autoantibodies (Höftberger, 2015; Lai et al., 2009; Lancaster et al., 2010).  
Another trigger of AIE is presumed to be virus associated. For instance, in herpes 
simplex virus encephalitis (HSE), 20 % of patients who suffer a relapse display no 
viral detection and are not responsive to anti-viral medications but display behavioral 
changes, which represent a main symptom for AIE (Höftberger, 2015). In addition, 
several studies could detect NMDAR autoantibodies in relapsed patients with former 
HSE diagnosis (Armangue et al., 2014; Prüss et al., 2012; Schein et al., 2017). 
These observations suggest that neurologic autoimmunity might be triggered by 
viral infections through molecular mimicry of neuronal antigens by the virus or 
through  virus induced lysis of neuronal cells which then activates the immune 
system to produce autoantibodies (Höftberger, 2015). 
As an additional trigger vaccination has been discussed for its involvement in AIE 
and other autoimmune diseases. It has been reported for a few cases that after 
vaccination of H1N1 influenza, tetanus, diphtheria, pertussis, poliomyelitis and 
Japanese encephalitis, NMDAR encephalitis had occurred (Dalmau et al., 2011; 
Hofmann et al., 2011; Wang, 2017). However, this might be a coincidence and which 
other factors are also involved in the origin of autoimmune diseases, such as genetic 
predisposition has to be further investigated (Perdan-Pirkmajer et al., 2012; 
Shoenfeld et al., 2000; Vadalà et al., 2017; Wang, 2017).  
Besides the possible triggers, such as tumor or viral association, the main cause for 
AIE for a large amount of patients remains unknown (Höftberger, 2015). Therefore, 
research of the immune system of patients and analysis of their autoantibody 
repertoire are necessary to improve the understanding of immunological 
deregulation that leads to AIE. 
 
1.2. N-Methyl-D-Aspartate Receptor Encephalitis 
About a decade ago, in 2007, a new form of autoimmune encephalitis was identified 
by Dalmau and colleges, known as NMDAR encephalitis. Since then, it has been 
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shown that in 70 % of patients, disease manifestation starts with a prodromal phase 
including headache, fever, nausea, vomiting, diarrhea or upper respiratory-tract 
symptoms (Dalmau et al., 2011). As the disease progresses many patients develop 
psychiatric symptoms such as anxiety, agitation, psychosis, memory deficits and 
speech reduction (Höftberger, 2015). In more severe cases, a multistage processing 
NMDAR encephalitis occurs. Here, patients develop abnormal movement, seizures, 
decreased consciousness, coma, breathing instability (hypoventilation) and display 
autonomic instability (Dalmau et al., 2007; 2009; Höftberger, 2015). Nonetheless, 
also milder forms of NMDAR encephalitis have been reported, whereas isolated 
psychiatric symptoms, seizures or repetitive movements (dystonia) appear 
(Niehusmann et al., 2009; Rubio-Agustí et al., 2011). 
The exact frequency of NMDAR encephalitis is unknown, but epidemiological 
studies suggest that it is the most common cause of non-infectious encephalitis, 
apart from acute demyelinating encephalomyelitis (ADEM) in children (Granerod et 
al., 2010). A Californian encephalitis project, investigating encephalitis patients 
younger than 30 years, identified more cases with NMDAR encephalitis than viral 
triggers such as herpes simplex virus (Gable et al., 2012). Another study in Germany 
identified, that 1 % of all patients diagnosed with encephalitis of unknown origin 
between 18 and 35 years treated in the intensive care unit (ICU) were eventually 
diagnosed to have NMDAR encephalitis (Pruss et al., 2010). 
About 80 % of patients with NMDAR encephalitis are women and the mean age is 
about 23 years of age (Dalmau et al., 2008; Titulaer et al., 2013). A study by Titulaer 
and colleges in 2013 link 38 % of patients with a tumor, mostly ovarian teratoma 
(94 %). The distribution among age, sex and the detection of a tumor reveals that 
the disease occurs in children of both sexes and in younger females. Interestingly, 
the discovery of the tumor and its subsequent removal perceptibly improves the 
disease outcome (Dalmau et al., 2008; Iizuka et al., 2008; Irani et al., 2010; Rypulak 
et al., 2016). 
The disease can often be so severe that 77 % of NMDAR encephalitis patients have 
to be admitted to an ICU. However about half of the patients benefit of first-line 
therapy which is composed of immunotherapy with the administration of steroids 
and intravenous immunoglobulins and with plasma exchange (Titulaer et al., 2013). 
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Nonetheless, several studies outline that cognitive impairments in executive 
functions and memory persist after treatment, implicating that earlier and more 
aggressive treatment might be necessary (Finke et al., 2012; Houtrow et al., 2012). 
Second-line therapy consists of rituximab in combination with cyclophosphamide 
(Dalmau et al., 2011). Rituximab is a chimeric monoclonal antibody against        
CD20-positive B cells inducing B cell depletion that may involve antibody-dependent 
cytotoxicity, complement-mediated lysis, or apoptosis (Dalakas, 2008; Edwards et 
al., 2004; Gopal and Press, 1999; McLaughlin, 2001). Cyclophosphamide is an 
alkylating agent, functioning as a general cytostatic and is frequently used as a 
broad approach in cancer therapy as well as in treatment of autoimmune diseases 
(Teles et al., 2017). Second-line therapy led to a significant decrease of relapses 
observed in a study by Titulaer and colleges in 2013. However, as the disease 
discovery was quite recently in 2007, long-term outcome studies are still pending. 
Generally, NMDAR autoantibodies titers changes in CSF can be observed during 
relapses and might be useful to complement clinical assessment, (Gresa-Arribas et 
al., 2014). Yet, the serum titer correlation between patients is poor, and the 
correlation between CSF and serum titers is not fully understood. 
The preliminary survival rate of NMDAR encephalitis is estimated at 93 – 96 %, 
whereas earlier treatment through sooner disease recognition might improve this 
number and probably the long-term outcome (Dalmau et al., 2008, 2011; Titulaer et 
al., 2013). A favorable outcome was accompanied by low severity of symptoms 
within four weeks of disease onset, early treatment, no ICU hospitalization and 
longer follow-up after treatment (Titulaer et al., 2013). Nonetheless, although about 
80 % of NMDAR encephalitis patients recover completely or at least partially, it can 
take up to 18 months for signs of recovery to appear (Titulaer et al., 2013). 
 
1.3. The N-Methyl-D-Aspartate Receptor 
The NMDAR was named after one of its ligand, NMDA, which is an amino acid 
derivative originally used in neuroscience research to mimic the action of glutamate, 
which in turn is the natural ligand that leads to opening of the NMDAR ion channel 
(Curtis and Watkins, 1960; Curtis and Watkins, 1963; Stone and Burton, 1988). 
Generally, the NMDAR belongs to the family of glutamate receptors, which are 
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primarily located on neurons and are synaptic receptors. The family is represented 
by metabotropic glutamate receptors that indirectly activate ion channels through    
G coupled receptors and ionotropic glutamate receptors that form an ion channel 
and are activated by glutamate binding. The tetrameric NMDAR, an ionotropic 
glutamate receptor, is a heterogeneous structure composed of two NR1 subunits 
and two of various combinations of NR2 or NR3 subunits (Chazot et al., 1994; 
Monyer et al., 1992; Schorge and Colquhoun, 2003; Ulbrich and Isacoff, 2007, 2008) 
(Fig. 1B). The NR1 subunit is expressed by a single gene (GluN1) but splicing leads 
to the expression of eight different isoforms throughout the brain (Sugihara et al., 
1992; Zukin and Bennett, 1995). The NR2 subunit is expressed by four (GluN2A-D) 
and the NR3 subunit by two genes (GluN3A-B) (Chatterton et al., 2002; Sucher et 
al., 1996). It is known that during development NR2B and NR2D are predominantly 
expressed earlier, their expression decreases while the expression of NR2A and 
NR2C increases (Monyer et al., 1994). All NMDARs harbor an extracellular amino-
terminal domain (ATD), a agonist binding domain (ABD) with two chains (S1 and 
S2), a membrane domain with three transmembrane domains (M1, M3, M4), one 
membrane domain with a reentrant loop (M2) and a carboxyl-terminal domain (CTD) 
reachable for signaling proteins (Vyklicky et al., 2014) (Fig. 1 A).  
There are several known antagonists targeting different domains of the NMDAR. Of 
note, magnesium ions are located in the membrane domain, phencyclidine (PCP) 
and ketamine are channel blockers and zinc ions and ifenprodil localize to the ATD 
of the NMDAR (Hansen et al., 2018) (Fig. 1 B). A previously reported study using 
CSF of NMDAR encephalitis patients has detected that the ATD region of the 
NMDAR and especially the amino acid N368 as crucial for autoantibody binding, as 
antibodies of patients do no longer bind to a N368Q mutated form of the NMDAR, 





Figure 1 Structure of N-Methyl-D-aspartate receptors. 
A: Linear and structural representation of the different domains of one NMDAR subunit. 
Each NMDAR subunit is comprised of an amino-terminal domain (ATD), a agonist binding 
domain (ABD) with the S1 and S2 segments forming a bilobed structure with an upper lobe 
(D1) and lower lobe (D2) and with linkers to the transmembrane domain (TMD). The 
cytoplasmatic carboxyl-terminal domain (CTD) contains signaling molecules that influence 
the NMDAR. B: The model of a NMDAR tetramer containing two NR1 (GluN1) and two NR2 
(GluN2) subunits and a schematic view of its binding partners. Opening of the NMDAR pore 
needs the binding of both glycine (or D-serine) and glutamate at the ABD. Additionally, the 
depolarization via AMPA or kainate receptors is necessary to remove the magnesium (Mg2+) 
that blocks the NMDAR channel in the TMD. The opening allows the sodium (Na+) and 
calcium (Ca2+) ions into the cell and enables efflux of potassium (K+) ions. Further binding 
sites have been identified such as the noncompetitive receptor antagonist site for 
phencyclidine (PCP) and ketamine. Further binding partners in the ATD of the NMDAR, 
such as zinc and ifenprodil also modulate the receptor activity. For NMDAR encephalitis, 
several studies could reveal that mutation of the N368 amino acid in the ATD region of the 
NR1 subunit leads to a rejection of patients’ antibodies bindings. Positive (PAMs) and 
negative allosteric modulators (NAMs) are highlighted indicated to which subunit they 
belong to. (adapted from Hansen et al., 2018). 
 
Functionally, the NMDAR, located at the postsynaptic membrane, is important for 
the communication between neurons through synaptic transmission. The NMDAR 
operates as a coincidence detector and therefore as an integrator of synaptic activity 
(Madden, 2002). In addition to the co-agonists glutamate and glycine, or D-serine, 
the NMDAR requires the depolarization of the membrane via AMPAR and kainate 
receptors. This initiate the release of the blocked magnesium ion in the NMDAR 
channel of its transmembrane domain and calcium and sodium ions can enter and 
potassium ions can leave the cell which leads to depolarization and thus resulting 
in communication between cells. 
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1.4. The N-Methyl-D-Aspartate Receptor in Health and Disease 
Previously, the NMDAR has been associated, besides NMDAR encephalitis, with 
various diseases including certain neurodegenerative diseases such as Alzheimer’s 
disease or Huntington’s disease, schizophrenia, addiction, stroke and epilepsy (Lau 
and Zukin, 2007; Parsons and Raymond, 2014). An important function of the 
NMDAR is supposed to be its involvement in learning and memory due to a process 
called long-term potentiation (LTP) or long-term depression (LTD). LTP can be 
induced through simultaneous activation of pre- and postsynaptic neurons. The 
resulting maximal calcium influx stimulates intracellular signaling cascades, which 
subsequently lead to a strengthening of connection between neurons. LTD is 
caused by repeated activation of only the presynaptic neuron, consequently 
resulting in low stimulation of the postsynaptic neuron, which is presumably the 
cause of weakening connection between neurons. However, these processes are 
only possible due to the NMDAR functioning as a coincidence detector which is 
essential for several forms of synaptic plasticity (Lüscher and Malenka, 2012). For 
example, in Alzheimer’s disease, the block of LTP and eliciting of LTD via amyloid 
beta (Aβ) oligomers is believed to be the reason for early cognitive decline 
(Kamenetz et al., 2003). 
Besides its contribution to development of memory and learning, the NMDAR is also 
involved in a process named excitotoxicity leading to neurodegeneration (Beal, 
1992). Excitotoxicity is caused via excessive activation of the NMDAR. These 
stimulations result in an huge influx of calcium that induces cell death throughout 
the brain (Choi, 1987; Choi et al., 1988). In Huntington’s disease the degeneration 
of neurons are thought to be caused by excessive NMDAR signaling that induced 
excitotoxicity (Heng et al., 2009; Sepers and Raymond, 2014). Prevention of 
excitotoxicity plays also a major role in treatment of ischemic stroke in order to 
prevent neuronal damage. Research on NMDAR antagonists revealed their 
neuroprotective properties (Muir and Lees, 1995; Simon et al., 1984). However, a 
big challenge to treat patients is that the healthy tissue is also effected by NMDAR 
antagonists and drug specificity has to be further investigated (Dingledine et al., 
1999).  
The first identified antagonists of the NMDAR, such as PCP and ketamine, used as 
anesthetic drugs display various adverse side effects, which led to the removal of 
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PCP from clinical use (Javitt and Zukin, 1991). Mild intoxication of these anesthetic 
drugs could mimic the symptoms of schizophrenia suggesting that the disturbance 
of NMDAR function plays a major role in the disease (Javitt and Zukin, 1991; Krystal 
et al., 1994). Higher concentrations of PCP lead to severe rigidity and catatonia and 
severe PCP intoxication was accompanied by coma, respiratory failure and seizures 
(Burns et al., 1975; Liden et al., 1975; Pearce, 1976; Walberg et al., 1983). These 
symptoms are similar to different known disease stages of NMDAR encephalitis, 
which have been described as hallucination, agitation and psychosis. Later, the 
multistage clinical course of NMDAR encephalitis leads to unresponsiveness with 
catatonic features, coma and respiratory failure (Dalmau et al., 2011) (Fig. 2 A,B).  
A comparison of NMDAR encephalitis with research in PCP abuse as a 
schizophrenia model could also reveal new understandings of the disease 
pathomechanisms in NMDAR encephalitis (Masdeu et al., 2016) (Fig. 2C). 
In previous studies, it was suggested that autoantibodies against the NMDAR are 
the main cause that induce the symptoms of the disease. In vitro experiments with 
patients’ CSF revealed a reduction of synaptic NMDAR-mediated currents in whole-
cell patch-clamp recordings of hippocampal neurons (Hughes et al., 2010). Similar 
to pharmacological NMDAR antagonists, patients’ CSF samples reduced surface 
NMDAR levels through crosslinking and internalization of the receptor (Hughes et 
al., 2010; Moscato et al., 2014). In vivo injection of patients’ CSF into mice and 
subsequent behavioral studies could partly mimic the patients’ symptoms such as 
progressive memory deficits (Planagumà et al., 2015). Overall, NMDAR encephalitis 
has been explained as a multistage disease due to a progressive NMDAR reduction 
through binding, crosslinking and internalization of the patients’ NMDAR via 
autoantibody binding. Here, varying titers are thought to be involved in its gradual 
internalization and worsening or progression of the disease (Dalmau et al., 2011) 























Figure 2 A psychoactive drug mimics symptoms of schizophrenia and NMDAR 
encephalitis: a common explanation for the pathogenesis of both diseases 
A: In NMDAR encephalitis patients initially undergo a prodromal phase with fever. As the 
clinical course gets worse they display agitation, psychosis and hallucinations etc., which 
also in a later state of the disease can lead to abnormal movement, coma and respiratory 
failure etc. Clinical improvement of the patient displays symptoms in a reverse manner.        
B: Studies have demonstrated that phencyclidine (PCP) in correlation to the concentration 
presents similar symptoms in comparison to the different states of the NMDAR encephalitis.  
C: It has been suggested that the NMDAR autoantibodies disturb the signal transduction of 
neuronal cells, which is demonstrated via the release of vesicles of the presynapse with the 
neurotransmitter glutamate and an activation through receptors of the postsynapse, such 
as the NMDAR (N-methyl-D-aspartate receptor) (green) and the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) (blue). It is believed that worsening 
depends on the autoantibody titer that induces internalization of the NMDAR, leading to a 
decrease of NMDAR in the long-term of the disease course. (Masdeu et al. 2016) 
 
All these studies support the hypothesis that autoantibodies against the NMDAR are 
involved and causal in the pathogenicity of NMDAR encephalitis, but ultimate proof 
is missing as CSF samples contain a variety of different antibodies. In addition, 
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some symptoms such as epileptic seizures have been associated with increase or 
unchanged NMDAR expression at the synapse (Kalev-Zylinska et al., 2009; 
Wasterlain et al., 2013) and therefore cannot be explained by the current model. In 
addition, the variable clinical picture of NMDAR encephalitis raises the question, 
whether non-NMDAR binding antibodies do exist in the CSF and are involved in the 
disease picture. Furthermore, little is known about the origin of the disease, as 
antibodies are produced by B cells. The question arise which part of the B cell 
development might be deregulated to break central tolerance and is involved in the 
emergence of NMDAR autoantibodies. 
 
1.5. Checkpoints of Central Tolerance that Might Induce the Generation of 
N-Methyl-D-Aspartate Receptor Autoantibodies 
The human immune system is constituted of two subsystems. The fast innate 
immune system, which includes the anatomic barriers, the complement system and 
the cellular barriers as well as the adaptive immune system which allows for a 
stronger and highly specific reaction through recognition of individual pathogenic 
antigens. To initiate adaptive immunity, antigen presenting cells of the innate 
immune system, such as dendritic cells (DC), carry captured and degraded 
pathogen antigens to the peripheral lymphoid organs. Antigens of intracellular 
pathogens are presented on the major histocompatibility complex (MHC) class I, 
whereas extracellular pathogenic motives are phagocytosed and presented on MHC 
class II that activated CD4+ T helper cells and are able to prime and activate B cells 
(Trombetta and Mellman, 2005). Activated B cells comprise the humoral immunity 
by secreting antibodies that can bind and neutralize pathogens and toxins (Owens 
and Zeine, 1989). Deregulated B cells are thought to be a major contributor of 
autoimmune encephalitis by secreting autoantibodies that target brain structures. 
Generally, highly effective immune responses are tightly controlled to differentiate 
between self and foreign antigens. In order to prevent autoimmune diseases several 
checkpoints in the development of B cells help to distinguish self and non-self-
antigens (Meffre and Wardemann, 2008; Melchers, 2015).  
During B cell development and maturation, a highly diverse repertoire of B cells and 
antibodies are generated through somatic recombination. At the immunoglobulin 
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heavy (IgH) chain of the variable (V), diversity (D) and joining (J) segments a 
process called VDJ recombination takes place, leading to the formation of a pre-B 
cell receptor (BCR). A first checkpoint to prevent autoimmunity is the recognition of 
nuclear antigens by the pre-BCR in the microenvironment which leads to positive or 
negative selection of the pre-B cells (Almqvist and Mårtensson, 2012; Keenan et al., 
2008). In order to convert into immature B cells, similar to the VDJ recombination in 
the heavy chain, one of the light chain (IgL), kappa or lambda, rearranges its V and 
J segments and the second checkpoint follows. Presumably by a selection process 
depending on the strength of the interaction of BCRs with the autoantigens in the 
bone marrow, the autoreactivity decreases from early immature cells of 76 % to 
about 40 % in emigrated immature cells (Melchers and Rolink, 2006; Wardemann 
et al., 2003). At the third checkpoint, these immature B cells migrate to the spleen 
where autoantigens induce anergy or apoptosis leading to a further reduction of 
20 % autoreactivity (Wardemann et al., 2003). As the now mature naïve B cells 
circulate the body, anergic B cells need to maintain their unresponsiveness to 
prevent autoimmunity (Merrell et al., 2006). 
In order to activate naïve B cells to convert into antibody secreting cells, such as 
plasma blasts and plasma cells, or function as memory B cells, the T cell dependent 
activation takes place in the secondary lymphoid organs (Fig. 3). The naïve B cell 
takes up an antigen and presents it via the MHC class II to a matching T follicular 
helper cell (TFH) at the border of the T cell zone and B cell follicle, leading to B cell 
proliferation (Lane et al., 1992) (Fig.3 a). There are two main pathways how B cells 
differentiate into plasma cells and memory B cells, depending on high affinity B cell-
T cell interaction (Schwickert et al., 2011). The first pathway resulting in low affinity 
antibodies is located outside of the germinal center (GC) and these B cells 
differentiate into extrafollicular short-lived plasma cells and some convert to            
GC-independent memory B cells, which are both able to undergo class switch-
recombination (CSR) from IgM to IgG, IgA, or IgE (Kaji et al., 2012; Kurosaki et al., 
2015) (Fig. 3 b, c).  
The second pathway inside the GC initiates the process of affinity maturation that 
generates even stronger affinity and non-autoreactive antibodies. Affinity and 
reactivity to self serve as a fourth checkpoint to prevent autoimmunity. Affinity 
maturation in the dark zone is mediated by the activation-induced cytidine 
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deaminase (AID), the main regulator of CSR and somatic hypermutation (SHM) in 
B cells (Muramatsu et al., 2000; Revy et al., 2000) (Fig. 3 d). In the light zone, 
follicular dendritic cells (FDC) present antigens to B cells. Depending on the 
interaction, low affinity leads to apoptosis of B cells and high affinity results in 
positive selection. B cells that recognize self-antigens are mostly eliminated in this 
process, an exception are rare antigens or antigens expressed in distal tissue such 
as brain epitopes, which might be a cause for autoimmunity (Chan et al., 2012). 
After each circle, the surviving B cells either differentiate into long-lived plasma cells, 
memory B cells or reenter the GC circle to continue affinity maturation (Heesters et 
al., 2014) (Fig. e, f). In NMDAR encephalitis, autoantibody producing cells are 
thought to be initially stimulated in the periphery, whereas priming of autoantibody 
producing B cells are suspected to begin in GC nearby NMDAR expressing tumors. 
Subsequently, B cells that were primed against the NMDAR in the germinal centers 
near to ovarian teratomas could reach through the deep cervical lymph node into 
the CSF (Titulaer, et al., 2013; Dalmau, 2016). Nonetheless, the exact underlying 
mechanism and at which checkpoint of B cell activation and maturation central 







Figure 3 T cell dependent and independent B cell activation. 
In the secondary lymphoid organs antigens are presented by dendritic cells to native T cell 
leading to migration to the border of the T cell zone and the B cell follicle. Antigen-activated 
B cells interact with the activated T cells and both move to the outer follicles, where 
proliferation of B cells take place (a). Afterwards, one of the three following differentiation 
occurs: (b) some B cells become short-lived plasma cells, (c) some convert into germinal 
center (GC) independent memory B cells and (d) other B cells undergo rapid proliferation 
and develop a GC. In the dark zone, clonal expansion together with somatic hypermutation 
improves the diversification of the B cell receptor (BCR). In the light zone, follicular dendritic 
cells (FDC) antigen complex and antigen specific T follicular helper (TFH) cells interact with 
the B cells and affinity selection is accomplished. The B cell can either reenter the circle or 
leaves the GC as a memory B cell (e) or a long-lived plasma cell (f). The arrows symbolize 
the fate of the cells, whereas strong signals are represented by bold arrows, weak signals 
are depicted by narrow arrows. TCR (T cell receptor), MHC (major histocompatibility 
complex). (Kurosaki et al., 2015). 
 
Another disruption in central tolerance might be comprised by natural occurring 
autoantibodies (NABs). These are generated by a presumed B cell subtype 
predominantly in the fetal omentum to protect newborns but also in adults in the liver 
and are thought to be generated spontaneously (Kantor and Herzenberg, 1993; 
Panda and Ding, 2015). NABs are often polyreactive and display germline 
immunoglobulin (Ig) genes with no or little somatic hypermutation and low affinity 
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(Baccala et al., 1989; Chen et al., 1991). Functionally, they are thought to clear the 
biological waste by monitoring the tissue homeostasis via clearance of cellular 
debris in order to neutralize the pro-inflammatory properties and therefore are 
thought to be beneficial (Binder, 2012). In conclusion, despite the benefit of these 
NAB producing B cells, the partial lack of central tolerance to ignore these 
autoantibody-producing B cells in the immune system might be a further explanation 
for the origin of autoimmune diseases, such as NMDAR encephalitis. However, if 
NABs targeting NMDAR do exist in NMDAR encephalitis patients and whether they 
are involved in the emergence of the disease is a highly discussed question.  
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1.6. Aim of this Thesis 
NMDAR encephalitis has been identified as one of the most common autoimmune 
encephalitides targeting extracellular neuronal antigens. To date, the pathological 
mechanism of the emergence of this autoimmune encephalitis has not been defined, 
leaving therapeutic interventions to be quite broad. Despite treatment, recovery is 
often slow and patients may retain some disturbances in their cognition and 
impairments in memory can persist. So far, known disease associated triggers are 
quite diverse reaching from cancer to viral infections to unknown causes. As high 
levels of NMDAR autoantibodies titers in the CSF are a hallmark of the disease, it 
is thought that these autoantibodies against the NMDAR might be the main cause 
of the disease symptoms, but direct proof is missing, as further autoantibodies could 
also play a role in the disease process. 
One way to a better understanding of the disease pathogenesis is to explore the 
human monoclonal autoantibody repertoire of NMDAR encephalitis patients. 
In this study, we specifically aimed to: 
1. Generate human monoclonal autoantibodies of NMDAR encephalitis patients 
to address the question if NR1 autoantibodies alone are sufficient to induce 
neurological changes. 
I. Characterize different NR1 autoantibodies by defining whether their 
target epitope is conserved to discuss possible therapeutic 
interventions. 
II. Analyze the autoantibody repertoire towards somatic hypermutations 
as indications for germinal center reactions to gain new insights in the 
origin and pathogenic process behind the development of NMDAR 
encephalitis. 
III. Further to elucidate the contribution of natural occurring 
autoantibodies (NABs) in the autoantibody repertoire to the 
emergence of NMDAR encephalitis and discuss whether NABs are 
pathogenic in the disease. 
2. Define the contribution of antibody secreting cells and memory B cells in the 
CSF to the severity of NMDAR encephalitis. In detail, to determine the percentage 
of cells in the CSF that are NR1 autoantibody specific and characterize non-NR1 
specific immune cells. 
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3.1. Highlights of this Thesis 
In this study, we examined the pathogenic mechanisms of NMDAR encephalitis by 
investigating the antibody repertoire of NMDAR encephalitis patients via the 
generation and characterization of patient derived monoclonal antibodies. 
1. The human monoclonal NMDAR autoantibodies were subsequently used to 
perform functional assays. Here, incubation of hippocampal neurons with the 
NMDAR autoantibodies lead to downregulation of synaptic NMDAR clusters and a 
reduction in NMDA-induced calcium influx. Additionally, electrophysiological 
changes were observed. These findings constitute the final proof that NMDAR 
autoantibodies alone are able to induce pathological changes at critical neuronal 
structures. 
I. All identified NMDAR autoantibodies could no longer bind the 
NMDAR after a point mutation in a main immunogenic epitope, 
suggesting a common binding motive. 
II. Our study revealed high affinity NMDAR autoantibodies with minor 
somatic hypermutation highlighting the pathogenic potential of 
deregulated germinal center reactions. 
III. But we also detected low affinity NMDAR autoantibodies without 
somatic hypermutation, so called NABs, that showed pathogenic 
properties, indicating incomplete central tolerance. 
 
2. The variable clinical disease picture of NMDAR encephalitis questioned 
whether additional autoreactivity besides NR1 specific autoimmunity might play a 
role in pathogenesis. Indeed, only 6 % of all detected antibody secreting cells and 
memory B cells were identified to be NR1 specific. Of note, the majority of the non-
NR1 antibodies targeted particular epitopes on brain sections, pointing towards a 
possible role of these other autoantibodies in NMDAR encephalitis. 
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3.2. NR1 Autoantibodies Alone Are Sufficient to Decrease the Number of N-
Methyl-D-Aspartate Receptors in Hippocampal Neurons 
Previous work with NMDAR encephalitis patients’ CSF or serum could demonstrate 
that synaptic NMDAR clusters were downregulated in hippocampal neurons and 
electrophysiological experiments revealed reductions of NMDAR-mediated currents 
upon autoantibody treatment (Hughes et al., 2010; Mikasova et al., 2012; Moscato 
et al., 2014; Planagumà et al., 2015; Pruss et al., 2010). However, in these studies 
human CSF, serum or whole Ig fractions of patients’ CSF including possible non-
NMDAR antibodies were used, making it questionable whether additional 
autoantibodies contribute to observed changes. Here, our study with purified human 
monoclonal NMDAR autoantibodies, generated from NMDAR encephalitis patients’ 
CSF, substantiated the final proof that NMDAR autoantibodies are sufficient to 
induce electrophysiological and morphological changes, such as NMDAR cluster 
downregulation and decreased calcium influx when stimulated with NMDA in 
hippocampal neurons (Kreye and Wenke et al., 2016). In line, subsequent and 
independent studies using CSF samples as well as peripheral blood mononuclear 
cells (PBMCs) confirmed our results, verifying that human monoclonal NMDAR 
autoantibodies of NMDAR encephalitis patients specifically reduce NMDAR-
mediated synaptic currents and initiate NMDAR cluster downregulation (Malviya et 
al., 2017; Sharma et al., 2018). In addition, in vivo experiments showed that 
autoantibodies can induce memory deficits and similar to the NMDAR inhibitor 
MK801, cause increased locomotor activity (Sharma et al., 2018). As a conclusion, 
data of independent experiments demonstrates that NMDAR autoantibodies alone 
can induce functional changes in neurons to disturb signaling and are sufficient to 
provoke the main symptoms of NMDAR encephalitis. 
Discussing pathological mechanisms of NMDAR encephalitis in more detail, one 
has to point out the occurrence of memory B cells in the patients’ CSF. Here, it is of 
interest, that relapses occur in about one quarter of NMDAR encephalitis patients 
(Gabilondo et al., 2011). It is not fully understood, why patients relapse after 
treatment. We could show that a third of all identified NR1 autoantibody producing 
cells are indeed memory B cells. These findings strengthen our hypothesis that 
relapses might occur due to reactivation and differentiation of NR1 specific memory 
B cells. This hypothesis is supported by the fact that therapeutic intervention with 
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rituximab, a CD20 autoantibody targeting B cells and memory B cells can prevent 
relapses in NMDAR encephalitis patients in clinical use (Titulaer et al., 2013). 
In future, the human monoclonal autoantibodies obtained in this study could be 
interesting for clinical use. As efficient recovery from NMDAR encephalitis can be 
directly correlated with decreasing CSF autoantibody titers, the same is true for 
disease relapses which go in line with increased autoantibody titers (Gresa-Arribas 
et al., 2014). Yet, comparisons between patients’ CSF titers are intricate (Gresa-
Arribas et al., 2014). Using the identified monoclonal NR1 autoantibodies, molecular 
features such as the influence of avidity and affinity in NMDAR encephalitis could 
be investigated in detail in further studies. In long-term, this information might be 
leading to the use of monoclonal NMDAR autoantibodies as a comparable standard 
within clinics. Which in turn might help to compare NMDAR encephalitis patients 
among each other and might serve as a prediction standard of NMDAR 
autoantibody titers to determine treatment options. 
 
3.2.1. The Target Region of N-Methyl-D-Aspartate Receptor Autoantibodies 
Might Be Broader than Expected 
NMDAR autoantibodies have been described to target a specific epitope in the 
amino-terminal domain (ATD) of the NR1 subunit, thus we address the question if 
different monoclonal NMDAR autoantibodies display similar binding properties. In 
general, antibodies target their native antigen epitope through the variable chains of 
the Ig, the complementarity-determining regions (CDRs), whereby CDR3 is 
considered to be the most important structure for high affinity antigen binding (Xu 
and Davis, 2000). Contact between the antibodies paratop and the antigen epitope 
is established through 15-22 amino acid residues of each of them, whereas the 
binding energy is contributed mostly by only 5 to 6 of these residues (Laver et al., 
1990). Except for the clonally expanded autoantibodies, the identified NMDAR 
autoantibodies in this study do not display similarities in their amino acid sequence 
of the CDR3. Nonetheless, they all seem to bind one small epitope in the ATD region 
of the NR1 subunit of the NMDAR. In 2012, a study by Gleichman and colleges 
demonstrated that binding of patients’ CSF antibodies is abolished when a point 
mutation at the ATD region of the NR1 subunit was introduced, exchanging 
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asparagine to glutamine at position 368 (N368Q). Similarly, the binding of our 
purified human monoclonal NMDAR autoantibodies was eliminated in HEK293T 
cells expressing the N368Q mutated NMDAR form. Therefore, it has been 
hypothesized that NMDAR autoantibodies target a small, common, immunogenic 
region, a phenomenon that has also been described for nicotinic acetylcholine 
receptors in myasthenia gravis, another autoimmune disease. This hypothesis is 
meanwhile contrasted by newer findings in which competitive binding assay 
experiments revealed that there was no interference among the human monoclonal 
NMDAR autoantibodies, 003-102, 003-109, 007-168 (unpublished data). Similar 
results were reported by Sharma and colleges in 2018. 
Interestingly, analyzing the protein structure of the ATD region, the identified amino 
acid N368 lies in the area that links two lopes resulting in a clamshell-like structure. 
The hinge between the clamshell-like structure forms binding sites for endogenous 
allosteric modulators of the NMDAR such as protons (H+) and zinc ions (Zn2+), which 
induce after binding structural rearrangements in the NMDAR agonist binding 
domain (Gielen et al., 2008). Thus, mutations in this area (N368) are potentially 
leading to conformational changes. In addition, a recent in vitro study with positive 
allosteric modulators could restore the NMDAR function altered by NMDAR 
encephalitis patients’ CSF, suggesting that a special conformation is required for 
NMDAR autoantibody binding (Warikoo et al., 2018). Taking these findings together, 
it seems more likely that the NMDAR autoantibodies do not compete for the exact 
same epitope, but further studies are pending. 
In conclusion, the area around the amino acid N368 is important for NMDAR 
autoantibody binding, but it is probably not the only binding domain for NMDAR 
autoantibodies. Additionally, conformational changes might prevent autoantibody 
binding and should be considered for potential therapeutic interventions. 
 
3.2.2. N-Methyl-D-Aspartate Receptor Autoantibodies Showed Minor Somatic 
Hypermutation after Germinal Center Reactions 
In general, somatic hypermutation, high affinity and class-switched IgG 
autoantibodies are indicative of germinal center reactions with the involvement of    
T cells, resembling a pathological process in which homeostatic pathway functions 
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are disturbed (Elkon and Casali, 2008). We could show, that compared to all 
antibodies in the repertoire, NR1 autoantibodies showed only minor hypermutation 
in their sequence, but still demonstrated high affinity binding that resulted in NMDAR 
internalization and functional inhibition of the receptor (Kreye and Wenke et al., 
2016). A subsequent study also reported minor somatic hypermutations and 
validated autoantibody functionality in vivo (Malviya et al., 2017). Taken together, it 
has been independently shown that high affinity NMDAR autoantibodies can be 
generated with minor somatic hypermutations. The existing somatic hypermutations 
in NMDAR autoantibodies indicate an important role for affinity maturation via 
germinal center reactions as a pathogenic factor in the development of NMDAR 
encephalitis. At least in lymphoid aggregates, that were dissected of teratomas of 
NMDAR encephalitis patients, germinal center reactions have been reported 
previously (Dabner et al., 2012). In addition, a recent study could also emphasize 
the importance of germinal center reactions in NMDAR encephalitis. They identified 
continuous high levels of IgM and IgG NR1 autoantibodies in the sera of NMDAR 
encephalitis patients suggesting a consistent production of NR1-IgG from 
continuously circulating activated B cells in germinal centers (Makuch et al., 2018). 
As germinal center reactions are dependent on TFH to sufficiently stimulate B cells 
during affinity maturation, it is of interest to investigate T cell dependency during the 
development of NMDAR encephalitis. Verification of the hypothesis that a 
continuous production of autoantibodies is necessary and subsequent research 
might even lead to new therapeutic interventions through targeting germinal center 
reactions. 
 
3.2.3. Natural Occurring Autoantibodies of the N-Methyl-D-Aspartate-
Receptor Are Present in the Repertoire of N-Methyl-D-Aspartate-
Receptor Encephalitis Patients 
During analysis we detected natural occurring autoantibodies (NABs) in the CSF of 
NMDAR encephalitis patients. In general, NABs are autoantibodies with no changes 
in the germline configuration, are present in the absence of known immunization 
and are thought to be a first line of defense against bacteria, viruses and parasites 
(Coutinho et al., 1995). Several studies could further show that NABs fulfill a 
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beneficial role in healthy individuals explaining their evolutionary existence and 
making them a possible therapeutic against diseases such as multiple sclerosis and 
Alzheimer’s disease (for a detailed review, see Wootla et al., 2015). In contrast, we 
could demonstrate that the NAB (003-109), which displays lower affinity to the NR1 
subunit than the mutated NR1 autoantibody (003-102) of the same patient, is still 
able to functionally disturb synaptic NMDAR-mediated currents (unpublished data). 
In line, a study by Malviya and colleges, in 2017, described a human monoclonal 
NR1 autoantibody with one hypermutation in each chain. Due to its low 
hypermutation, this antibody can be defined as a NAB (Coutinho et al., 1995). 
Intraventricular infusion of this NAB in mice demonstrated that synaptic NMDAR 
cluster density was decreased and memory impairment was observed (Malviya et 
al., 2017). Taken together, these results suggest that NR1 specific NABs can also 
be pathogenic, which is supported by the fact that NABs have been shown to play 
an important role in pathogenesis of other autoimmune diseases. For instance, in 
insulin-dependent diabetes mellitus, it has been shown that anti-insulin IgG 
autoantibodies arise from a natural antibody with germline configuration targeting 
insulin without affinity maturation (Ichiyoshi et al., 1995). In addition, NAB producing 
B cells can enter the germinal center pathway and mature, undergoing class switch 
and hypermutation, as a result converting to higher affinity autoantibodies (Casali 
and Schettino, 1996). Thus, regulation of NABs’ maturation in a direct or indirect 
way might be contributing to the emergence of autoimmune diseases (Avrameas, 
1991). In conclusion, NABs specifically targeting NR1 in the CSF repertoire of 
NMDAR encephalitis patients might contribute to disease manifestation in NMDAR 
encephalitis.  
 
3.2. The Majority of Autoantibodies in the Cerebrospinal Fluid Target other 
Neuronal Structures 
The detection of high NR1 autoantibody titers in the CSF of NMDAR encephalitis 
patients initially suggested a major contribution of these autoantibodies (Dalmau et 
al., 2008) and thus we presumed that a large proportion of antibody secreting cells 
in the CSF would be NR1 specific. Interestingly, we could only detect NR1 
autoantibodies in three out of eight patients and found that among all patients only 
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6 % of CSF derived antibodies reacted against the NR1 subunit. In line, additional 
studies generating human monoclonal autoantibodies demonstrated that only a few 
of the antibody producing cells and memory B cells in the CSF are positive for NR1 
autoantibodies. Earlier studies suggested that plasma cells of autoantibodies are 
also present in inflammatory brain infiltrates, indicating an additional location of 
antibody producing cells (Camdessanché et al., 2011; Martinez-Hernandez et al., 
2011; Tüzün et al., 2009). As plasma cells are able to produce over several 
thousands of antibodies per second (Alberts et al., 2002), NMDAR autoantibodies 
could reach high concentrations in the CSF, whereas the plasma cells themselves 
might be located not only in the CSF but also in the brain parenchyma. Using laser 
capture microdissection in the parenchyma of tissue samples of NMDAR 
encephalitis patients and subsequent messenger RNA purification and Ig 
sequencing could unveil whether cells secreting NR1 autoantibodies might be also 
and largely located in the brain tissue. 
Focusing on all CSF derived non-NR1 specific antibodies, it is of note that 95 % 
bound specifically to diverse brain-expressed epitopes, providing first indications for 
the strong variability in the clinical picture of NMDAR encephalitis patients. 
Unpublished data of immunoprecipitation and mass spectrometry experiments of 
the non-NR1 specific antibodies shows binding to already known antigens involved 
in other autoimmune encephalitis diseases, such as AMPAR 2, glial fibrillary acidic 
protein (GFAP) and inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) (Fang et al., 
2016; Jarius et al., 2014; Lai et al., 2009). Additionally, these three targets have 
been verified via cell based assays. However, if these human monoclonal 
autoantibodies disturb neuronal function is still under investigation. 
Interestingly, a young NMDAR encephalitis patient additionally suffered from 
asystole, repeated failure in heart contraction, and needed a transient pacemaker 
during the stay in the ICU. The patient fully recovered from NDMAR encephalitis 
after treatment and also no longer needed the pacemaker. One autoantibody of this 
patient targeted both, ITPR1 and ryanodine receptor 2, known to be expressed in 
myocardial cells. Indeed, the autoantibody could alter the contraction rates of 
myocardial rat cells in vitro compared to control antibody (unpublished data). All in 
all, this supports the hypothesis that the variable disease picture of NMDAR 
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encephalitis might be accompanied with symptoms arising from diverse 
autoantibodies. 
Furthermore, the detection of other autoantibodies gives rise to the question if only 
NR1 autoreactivity is causal for the initiation of the disease or if a general 
disturbance of central tolerance leads to the generation of several autoantibodies 





Autoimmune diseases can develop dependent on the appearance of diverse genetic 
and environmental factors. In NMDAR encephalitis, humoral autoimmunity is 
thought to play a major role. 
In this study, we highlighted the pathophysiological role of NMDAR autoantibodies 
and the B cell repertoire of NMDAR encephalitis patients. Analyzing the antibody 
repertoire of eight patients, we detected NR1 autoantibodies with germline 
configuration, so called NABs, as well as NR1 autoantibodies displaying somatic 
hypermutation and high affinity binding to the NMDAR. All autoantibodies targeting 
the NR1 subunit, including NABs, were physiologically functional, as they were able 
to efficiently bind the NMDAR and subsequently alter synaptic currents. Taken 
together, NMDAR autoantibodies are highly functional and are probably causal for 
major symptoms of NMDAR encephalitis patients as they are able to elicit drastic 
physiological alterations in neurons. 
Nonetheless, other autoantibodies have been detected in the autoantibody 
repertoire of NMDAR encephalitis patients, raising the question to what extend they 
contribute to the quite variable disease picture. Additionally, NMDAR encephalitis 
might not only be an isolated autoimmune reaction to the NMDAR, but a broader 
autoimmune response with severe disruptions in central tolerance. Here, further 
studies are necessary to illuminate what pathophysiological changes these non-
NMDAR autoantibodies are able to induce. All in all, we could show strong 
pathogenic effects of NMDAR autoantibodies and were able to contribute to a better 
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